6-K
OKYO Pharma Ltd (OKYO)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-16
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
March2023
CommissionFile Number: 001-41386
OKYOPharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9^th^Floor
107Cheapside
London
EC2V6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATIONCONTAINED IN THIS REPORT ON FORM 6-K
On March 30, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing that, it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company’s ADSs on NASDAQ at a price of US$1.41 per ADS, a copy of which is furnished as Exhibit 99.1
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
|---|---|---|
| Date:<br> March 30 2023 | By: | /s/ Keeren Shah |
| Name: | Keeren<br> Shah | |
| Title: | Chief<br> Financial Officer |
| 3 |
| --- |
EXHIBITINDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | News Announcement, dated March 30, 2023 |
| 4 |
| --- |
Exhibit99.1
DirectorAcquires Shares
Londonand New York, NY, 30 March, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company’s ADSs on NASDAQ at a price of US$1.41 per ADS (which would be equivalent to the purchase of 715,000 ordinary shares of no par value (“Ordinary Shares”) at a price of £0.0176 each).
| 1. | Details<br> of PDMR / person closely associated | |
|---|---|---|
| a) | Name | Gabriele<br> Cerrone |
| 2. | Reason<br> for the notification | |
| a) | Position<br> / status | Chairman |
| b) | Initial<br> notification /amendment | Initial<br> notification |
| 3. | Details<br> of the issuer | |
| a) | Name | OKYO<br> Pharma Limited |
| b) | LEI | 213800VVN5CB56Y15A05 |
| 4. | Details<br> of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and<br> (iv) each place where transactions have been conducted | |
| a) | Description<br> of the financial instrument | ADSs<br> representing 65 Ordinary Shares of no par value |
| b) | Identification<br> code of the Financial Instrument | ISIN<br> for OKYO Pharma Limited GG00BD3FV870 |
| c) | Nature<br> of the transaction | Market<br> Purchase |
| --- | --- | --- |
| d) | Price(s)<br> and volume(s) | $1.41<br>– 11,000 |
| f) | Date<br> of the transaction | 28<br> March 2023 |
| g) | Place<br> of the transaction | NASDAQ |
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
|---|---|---|
| Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| Broker<br><br> <br>**** | Robert Emmet, Optiva Securities Limited<br><br> <br>**** | +44 (0)20 3981 4173 |
Notesfor Editors:
AboutOKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.
AboutOK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.